Milestone Pharma wins FDA nod for self-administered nasal spray for PSVT The at-home treatment is designed to manage acute symptomatic episodes outside of emergency healthcare settings.

FDA approves Cardamyst, the Milestone Pharmaceuticals’ self-administered nasal spray for PSVT. A rapid at-home treatment for sudden rapid heart episodes, available in 2026.
#News #PSVT #CARDAMYST #FDAapproval #HeartHealth #MedicalNews

Milestone Pharma wins FDA nod for self-administered nasal spray for PSVT The at-home treatment is designed to manage acute symptomatic episodes outside of emergency healthcare settings.

FDA approves Cardamyst, the Milestone Pharmaceuticals’ self-administered nasal spray for PSVT. A rapid at-home treatment for sudden rapid heart episodes, available in 2026.
#News #PSVT #CARDAMYST #FDAapproval #HeartHealth #MedicalNews